Eli Lilly and Company

Equities

LLY

US5324571083

Pharmaceuticals

Market Closed - Nyse 01:30:02 30/04/2024 am IST Pre-market 04:49:10 pm
737.2 USD +0.50% Intraday chart for Eli Lilly and Company 786.5 +6.69%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Eli Lilly's Q1 Non-GAAP Earnings, Revenue Rise; 2024 Guidance Lifted MT
(LLY) ELI LILLY AND COMPANY Expects Fiscal Year 2024 EPS Range $13.50 - $14.00 MT
Earnings Flash (LLY) ELI LILLY AND COMPANY Reports Q1 Revenue $8.77B, vs. Street Est of $8.93B MT
Earnings Flash (LLY) ELI LILLY AND COMPANY Posts Q1 EPS $2.58, vs. Street Est of $2.49 MT
Eli Lilly beats profit estimates on diabetes and weight-loss drug strength RE
Futures drift lower as focus shifts to rate verdict RE
Equity Markets Rise With Key Earnings, Fed Decision in Focus MT
US Equity Markets Close Higher Monday Ahead of Earnings, Fed Meeting This Week MT
Equities Higher as Traders Await This Week's Key Earnings, Fed Decision MT
S&P 500 Companies' Latest Quarterly Results Mixed so Far, Oppenheimer Says MT
Big tech saves the day, again Our Logo
Habeck's 'pharma trip' - industry sees structural problems DP
Scholz pledges further support for the pharmaceutical industry DP
Scholz promises support for pharma sector in Germany as Merck invests RE
Global markets live: Bayer, PepsiCo, Halliburton, Spotify, Apple... Our Logo
Alzheimer's drug adoption in US slowed by doctors' skepticism RE
Alexandria Real Estate's Q1 FFO rises on stronger occupancy rates RE
Eli Lilly Acquires Injectables Manufacturing Facility in Wisconsin from Nexus Pharmaceuticals MT
Eli Lilly to acquire manufacturing facility from Nexus Pharma RE
Eli Lilly: agreement to purchase a Nexus plant in the USA CF
Eli Lilly and Company entered into a definitive agreement to acquire New Injectable Medicine Manufacturing Facility of Nexus Pharmaceuticals, Inc. CI
India's Biocon developing its own version of Wegovy, clinical trial likely next year RE
Top Stories at Midday: U.S. Bancorp, Abbott, Citizens Financial, First Horizon, Prologis, ASML, Travelers Report Earnings; Tesla Asks Shareholders Vote on Musk's Compensation; Eli Lilly Sleep Apnea Drug Trials Hit Primary Endpoints MT
Jefferies Raises Eli Lilly's Price Target to $895 From $885, Buy Rating Kept MT
Trending : Eli Lilly Weight-Loss Drug Works on Sleep Apnea DJ
Chart Eli Lilly and Company
More charts
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.5%); - immunology diseases (11.1%); - neurology (8.4%): primarily drugs used in treating depression and schizophrenia; - other (3.3%). Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
737.2 USD
Average target price
813.3 USD
Spread / Average Target
+10.33%
Consensus
  1. Stock Market
  2. Equities
  3. LLY Stock
  4. News Eli Lilly and Company
  5. Market Chatter: Eli Lilly Employees Reportedly Accuse US Factory Executive of Altering Documents